Dianthus Therapeutics, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -0.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.93 | $-0.90 | +3.2% | Beat | |
| Q1 FY26 | $-1.17 | $-0.85 | +27.4% | Beat | |
| Q4 FY25 | $-0.98 | $-1.43 | -45.9% | Miss | |
| Q3 FY25 | $-0.86 | $-0.97 | -12.8% | Miss | |
| Q2 FY25 | $-0.86 | $-0.88 | -2.3% | Miss | |
| Q1 FY25 | $-0.86 | $-0.82 | +4.7% | Beat | |
| Q4 FY24 | $-0.85 | $-0.81 | +4.7% | Beat | |
| Q3 FY24 | $-0.59 | $-0.74 | -25.4% | Miss | |
| Q2 FY24 | $-0.50 | $-0.51 | -2.0% | Miss | |
| Q1 FY24 | $-0.43 | $-0.54 | -25.6% | Miss | |
| Q4 FY23 | $-1.11 | $-0.71 | +36.0% | Beat | |
| Q3 FY23 | not reported | $-3.78 | not reported | not reported |
Back to DNTH overview · DNTH holders · DNTH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.